Fundamental And Clinical Evaluation of 9,3”-Diacetylmidecamycin in Pediatric Field

Yukio Iwasaki, Satoshi Iwata, Takefumi Kanemitsu, Keiji Jozaki, Haruki Hattori, Ryoh Wakabayashi, Yoshibumi Kojima, Keisuke Sunakawa, Tadao Oikawa, Mitsuru Osano, Yasuo Ichihashi

研究成果: Article査読

2 被引用数 (Scopus)

抄録

1. The dry syrup of MOM was administered orally to 17 patients mainly with heart deseases at doses of 10 mg/kg and 20 mg/kg. In 17 cases,the serum level was measured and in 4 cases, the urinary excretion rate including the metabolites of MOM. 2. The mean maximal concentrations were 0.54 mcg/ml at 30 minutes for the group of 10 mg/kg treatment and 0.33 mcg/ml at 1 hour for the group of 20mg/kg treatment.The dose response was not observed obviously in both groups. 3. In each of the cases, the sum of excretion rates of metabolites in the 24-hour urine was about 1%. 4. MOM was administered clinically to 39 cases with respiratory tract infections and the overall efficacy rate was 85%. 5. In this study, 5 strains of S. pyogenes were isolated and the eradication rate was60%. 6. Although severe side effects were not observed, gastrointestinal abnormalities like diarrhea and vomiting were seen in 3cases. 7. Any pediatric patient did not refuse taking.

本文言語English
ページ(範囲)429-437
ページ数9
ジャーナルthe japanese journal of antibiotics
35
2
DOI
出版ステータスPublished - 1982

ASJC Scopus subject areas

  • 微生物学(医療)
  • 薬理学(医学)
  • 感染症

フィンガープリント

「Fundamental And Clinical Evaluation of 9,3”-Diacetylmidecamycin in Pediatric Field」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル